Executive Summary
The success of a MedTech start-up depends on its ability to integrate innovation, business growth, and regulatory compliance. Each investment phase - from Pre-Seed to Series C - presents unique regulatory challenges and opportunities.
Understanding how to align regulatory milestones with funding rounds and effectively engage with the Notified Body (NB) can accelerate market access, attract investors, and ensure sustainable growth.
This article intends to analyze the typical journey of a Medical and In Vitro Diagnostic Devices start-up, mapping its development and financing phases to its regulatory maturity and identifying the key challenges and best practices at each stage.
Introduction - The Dynamic Landscape of MedTech Startups
The MedTech start-up ecosystem is one of the most dynamic and fast-evolving sectors in healthcare innovation. Over the past decade, the convergence of digital technologies, artificial intelligence, and advanced biomaterials has transformed how medical devices are conceived, developed, and commercialized.
Across Europe and globally, hundreds of start-ups are emerging each year - from university spin-offs exploring innovative diagnostic technologies to digital health companies redefining patient monitoring and care delivery. Venture capital investment in the MedTech sector continues to grow, driven by the increasing demand for data-driven, personalized, and minimally invasive solutions.
Yet, despite this momentum, the path from concept to commercialization in MedTech remains uniquely challenging. Unlike software or digital service start-ups, medical technology innovators must work within a highly regulated environment where clinical evidence, safety, and quality systems are as critical as innovation and speed.
These dual priorities - combining scientific and technical innovation with regulatory and market validation - often define whether a start-up succeeds or fails. The ability to plan a coherent regulatory strategy, engage early with a Notified Body, and align these milestones with investor expectations can make the difference between a promising prototype and a market-approved product.
In this context, understanding how investment phases (Pre-Seed, Seed, Series A, B, and C) align with regulatory maturity becomes crucial. Each phase brings distinct priorities:
- Early discovery and feasibility.
- Prototype validation.
- Clinical evidence generation.
- Regulatory Market Approval.
- Scale-up and internationalization.
In this article, I’ve explored that journey through my experience working with startups - examining how MedTech startups evolve across different stages, how their relationship with the Notified Body matures over time, and how a well-structured regulatory strategy can act not as a constraint, but as a strategic enabler for sustainable growth and investor confidence.
1. Pre-Seed Stage - concept and feasibility
Investment focus
At this initial phase, capital typically comes from founders, early angels, or public grants. The goal is to validate the clinical need and show technical feasibility.
Regulatory perspective
Even though the Notified Body is not yet involved, early regulatory thinking is critical. Key activities include:
- Defining the intended purpose, the clinical benefits and the risk class under MDR/IVDR.
- Identifying applicable General Safety and Performance Requirements (GSPRs) that may require clinical and technical evidence.
- Conducting a preliminary regulatory gap analysis.
Challenges
- Limited awareness of regulatory constraints among founders.
- Early design choices may conflict with future MDR/IVDR expectations.
- Investors often undervalue regulatory preparedness.
Best practices
- Engage a regulatory advisor early.
- Include a regulatory roadmap in the business plan to reassure investors, including a Clinical Development Plan early (See MDR, Annex XIV, Part A).
- Build an innovation narrative grounded in compliance feasibility.
2. Seed Stage - prototype and preclinical development
Investment focus
Seed funding supports prototype development, verification, and preclinical testing. The aim is to show technical and biological safety.
Regulatory perspective
This is the right time to start informal discussions with a Notified Body and begin implementing a Quality Management System (QMS) aligned with ISO 13485. Key regulatory deliverables:
- Verification and Validation (V&V) test plans.
- Preliminary risk management file.
- Draft technical documentation structure.
Challenges
- Balancing rapid iteration with documentation discipline.
- Budget constraints affecting testing and QMS implementation.
- Choosing the most appropriate NB with relevant device scope and expertise.
Best practices
- Include regulatory milestones in the investor pitch.
- Leverage public funding or accelerators focused on MedTech compliance.
- Ensure design controls are MDR/IVDR-compliant from the start.
3. Series A - clinical validation and regulatory submission
Investment focus
Series A funding is used to conduct clinical investigations, strengthen the team, and prepare for CE certification submission.
Regulatory perspective
The start-up now formally engages with the Notified Body for conformity assessment. Key deliverables include:
- Technical Documentation (Annex II and III).
- Clinical Evaluation Report (CER - MDR) or Performance Evaluation Report (PER - IVDR).
- Full QMS certification audit readiness.
Market Access and Health Technology Assessment (HTA)
While achieving CE marking is essential for market entry, securing reimbursement is equally critical for commercial success. Start-ups should begin early planning for Health Technology Assessment (HTA), which evaluates the clinical and economic value of the device for healthcare systems. Aligning clinical study design with HTA requirements can help generate the evidence needed not only for regulatory approval but also for favorable reimbursement decisions by health institutions.
Challenges
- Managing the high cost and complexity of clinical studies.
- Aligning documentation to NB expectations.
- Ensuring submission timelines fit investors’ return expectations.
Best practices
- Co-develop a regulatory timeline with investors and NB.
- Document clear evidence plans to support CE marking.
- Anticipate feedback loops with the NB to minimize delays.
The EU’s new Health Technology Assessment (HTA) system introduces Joint Scientific Consultations (JSCs), a chance for device developers to get early, coordinated advice from EU experts before running clinical studies. JSCs are open to medical devices and in vitro diagnostics (IVDs) that are likely to undergo future Joint Clinical Assessment, especially innovative, high impact, or high risk technologies. If your device is still in the planning stage for clinical investigations, you can apply for a JSC by submitting a request during one of the scheduled application windows set by the EU HTA Coordination Group. The process helps you understand what evidence EU countries will expect later, reducing duplication and saving time. For startups, this is a valuable opportunity to design the right studies from the beginning and avoid costly rework. You can find more information here: JSC Applications.
Insight - indicative regulatory timeline for investors
Understanding the rhythm of regulatory milestones can help investors assess progress and risk. A typical CE Certification journey may include:
- Pre-Seed: Intended purpose definition, preliminary risk classification, and early feasibility work.
- Seed: Prototype verification, initial QMS implementation, and preclinical validation.
- Series A: Clinical investigation and CE submission preparation.
- Series B: CE certificate issued, product launch, and PMS/PMCF activities. Consideration of HTA Assessment under EU 2021/2282.
- Series C: Global submissions (e.g., FDA, MDSAP) and regulatory harmonization.
Clear visibility of these stages enables investors to align funding tranches with objective regulatory achievements - reinforcing confidence and transparency in the startup’s trajectory.
4. Series B - CE marking and commercial launch
Investment focus
Series B capital accelerates manufacturing, commercialization, and early market entry in Europe and beyond.
Regulatory perspective
At this stage, the startup becomes a certified manufacturer and enters the post-market phase. Ongoing obligations include:
- Surveillance audits by the Notified Bodies.
- Maintenance of technical documentation.
- Implementation of Post-Market Surveillance (PMS) and Post-Market Clinical Follow-Up (PMCF) activities.
Challenges
- Scaling QMS processes while increasing production.
- Managing multiple audits and supplier controls.
- Maintaining compliance across distributed teams.
Best practices
- Treat the Notified Body as a strategic partner.
- Develop a compliance-driven company culture.
- Use real-world data to strengthen PMCF evidence and market positioning.
5. Series C - scale-up and global expansion
Investment focus
Series C funding drives internationalization, product diversification, and industrial scalability.
Regulatory perspective
The regulatory function evolves into a strategic pillar. The company coordinates global submissions (FDA, MDSAP etc.) while maintaining MDR/IVDR compliance. Key priorities:
- Global regulatory harmonization.
- Digital transformation of QMS (eQMS).
- Proactive regulatory intelligence.
Challenges
- Managing multiple regulatory frameworks simultaneously.
- Aligning change control processes across products and regions.
- Ensuring regulatory scalability supports rapid market growth.
Best practices
- Build a global compliance roadmap aligned with the corporate strategy.
- Establish cross-functional governance between QA/RA, R&D, and commercial teams.
- Use regulatory maturity as a differentiator during IPO or M&A negotiations.
Conclusion
For MedTech startups, regulation is not a hurdle - it is a growth enabler. Companies that align regulatory strategy with their investment trajectory build stronger investor confidence, accelerate market access, and achieve sustainable scalability.
By engaging with Notified Bodies early, adopting structured compliance frameworks, and integrating regulatory excellence into the company’s DNA, startups can transform from innovative ideas into trusted market leaders.
Key takeaways
- Regulatory maturity should evolve in parallel with investment rounds.
- Early interaction with Notified Bodies reduces time-to-market and funding risk.
- A proactive compliance culture drives both credibility and valuation.
Further resources - building regulatory knowledge
For Startups new to the CE Certification journey, developing regulatory knowledge early can save time and capital later. Key resources include:
- The European Commission’s MDR and IVDR guidance library, including documents from MDCG (Medical Device Coordination Group).
- Notified Body websites, which often provide free guidance on conformity assessment procedures and classification.
- National Competent Authorities for local regulatory requirements and public funding opportunities.
- Professional networks and training organizations for courses, webinars, and certification programs.
Investing in regulatory education empowers founders and investors alike to make evidence-based strategic decisions.
